What You Should Know:
– PathAI, a global leader in artificial intelligence (AI) and digital pathology solutions, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its digital pathology image management system, AISight® Dx, for use in primary diagnosis in clinical settings.
– The FDA clearance builds upon the platform’s initial 510(k) clearance for AISight Dx(Novo) in 2022, demonstrating PathAI’s ongoing commitment to innovation and delivering enhanced capabilities.
Accelerated Innovation Through Predetermined Change Control Plan
The FDA’s decision also included a Predetermined Change Control Plan (PCCP). This critical regulatory alignment allows PathAI to validate and implement specified major changes, such as additional displays, scanners, file formats, and browsers, into AISight Dx without requiring further 510(k) submissions. The approach is expected to accelerate future software updates and hardware integrations, enabling faster innovation while ensuring continued FDA compliance.
Maximizing Efficiency in Anatomic Pathology Workflows
AISight Dx is a cloud-native digital pathology platform meticulously designed to maximize efficiency in anatomic pathology workflows. The system offers a comprehensive suite of features, including intelligent case management, high-performance slide review, and seamless live collaboration. These capabilities help laboratories accelerate turnaround times and optimize pathologist productivity.
With integrated image management, synchronized multi-slide navigation, and robust annotation tools, AISight Dx aims to eliminate manual bottlenecks and support faster, more consistent diagnoses. The platform is built for interoperability, compliance, and scale, empowering anatomic pathology labs, hospital systems, and academic medical centers to modernize their operations and confidently deliver high-quality patient care.
“Digital pathology is the future of diagnostic medicine, empowering pathologists to work more efficiently and collaborate quickly without being limited to physical specimen review,” said Andy Beck, M.D., Ph.D., CEO of PathAI. “
